Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: II. The role of dysregulated growth factor signaling

Journal of Neuropathology and Experimental Neurology

Volumn 64, Issue 1, 2005, Pages 1-9

  Carroll, Steven L ^a,b   Stonecypher, Mark S ^a  

^a UNIVERSITY OF ALABAMA SCHOOL OF MEDICINE   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Growth factor; Mast cell; Neurofibromatosis; Schwann cell; Tumor progression; Tumor suppressor; Tumorigenesis

Indexed keywords

AMPHIREGULIN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIREGULIN; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; MIDKINE; NEU DIFFERENTIATION FACTOR; NEUROFIBROMIN; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN P53; SCATTER FACTOR; SEX HORMONE; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; GENE MUTATION; HUMAN; MAST CELL; NERVE SHEATH TUMOR; NEUROFIBROMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SCHWANN CELL; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 13244291508     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/64.1.1     Document Type: Review

References (71)

1. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 1997;278:51-57
2. Parada LF. Neurofibromatosis type 1. Biochim Biophys Acta 2000;71: M13-19
3. Gutmann DH. The neurofibromatoses: When less is more. Hum Mol Genet 2001;10:747-55
4. Carroll SL Stonecypher MS. Tumor suppressor mutations and growth factor signaling in the pathogenesis of NF1-associated peripheral nerve sheath tumors: I. The role of tumor suppressor mutations. J Neuropathol Exp Neurol 2004;63:1115-23
5. Riccardi VM. Growth-promoting factors in neurofibroma crude extracts. Ann NY Acad Sci 1986;486:206-26
6. Nogita T, Takehara K, Moro A, et al. Effect of platelet-poor plasma from patients with neurofibromatosis on the growth of cultured neurofibroma-derived fibroblast-like cells. Clin Exp Dermatol 1992;17:27-30
7. Agesen TH, Florenes VA, Molenaar WM, et al. Expression patterns of cell cycle components in sporadic and neurofibromatosis type I-related malignant peripheral nerve sheath tumors. J Neuropathol Exp Neurol 2005;63:74-81
8. Fallon KB, Havlioglu N, Hamilton LH, et al. Constitutive activation of the neuregulin-1/erbB signaling pathway promotes the proliferation of a human peripheral neuroepithelioma cell line. J Neurooncol 2004;66: 273-84
9. Druckrey H, Ivankovic S, Preussmann R. Teratogenic and carcinogenic effects in the offspring after single injection of ethylnitrosourea to pregnant rats. Nature 1966;210:1378-79
10. Jones EL, Searle CE, Smith WT. Tumors of the nervous system induced in rats by the neonatal administration of N-ethyl-N-nitrosourea. J Pathol 1973;109:123-39
11. Anderson LM, Hagiwara A, Kovatch RM, et al. Transplacental initiation of liver, lung, neurogenic and connective tissue tumors by N-nitroso compounds in mice. Fund Appl Toxicol 1989;12:604-20
12. Buzard GS, Enomoto T, Anderson LM, et al. Activation of neu by missense point mutation in the transmembrane domain in schwannomas induced in C3H/HeNCr mice by transplacental exposure to N-nitrosoethylurea. J Cancer Res Clin Oncol 1999;125:653-59
13. Diwan BA, Rehm S, Rice JM. Age- and dose-dependent transplacental carcinogenesis by N-nitrosoethylurea in Syrian golden hamsters. J Cancer Res Clin Oncol 1996;122:643-52
14. Rubinstein LJ, Conley FK, Herman MM. Studies on experimental malignant nerve sheath tumors maintained in tissue and organ culture systems: I. Light microscopy observations. Acta Neuropathol 1976;34: 277-91
15. Conley FK, Rubinstein LJ, Spence AM. Studies on experimental malignant nerve sheath tumors maintained in tissue and organ culture systems: II. Electron microscopy observations. Acta Neuropathol 1976; 34:293-310
16. Nikitin AY, Lennartz K, Pozharisski KM, Rajewsky MF. Rat model of the human "Triton" tumor: Direct genetic evidence for the myogenic differentiation capacity of schwannoma cells using the mutant neu gene as a cell lineage marker. Differentiation 1991;48:33-42
17. Muir D, Neubauer D, Lim IT, et al. Tumorigenic properties of neurofibromin-deficient neurofibroma Schwann cells. Am J Pathol 2001; 158:501-13
18. Kimura H, Fischer WH, Schubert D. Structure, expression and function of a schwannoma-derived growth factor. Nature 1990;348:257-60
19. Pfeiffer SE, Wechsler W. Biochemically differentiated neoplastic clone of Schwann cells. Proc Natl Acad Sci USA 1992;69:2885-89
20. Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p 185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 1987;84:7159-63
21. Di Marco E, Pierce JH, Knicley CL, et al. Transformation of NIH 3T3 cells by overexpression of the normal coding sequence of the rat neu gene. Mol Cell Biol 1990;10:3247-52
22. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986;45:649-57
23. Bargmann CI Weinberg RA. Oncogenic activation of the neu-encoded receptor protein by point mutation and deletion. EMBO J 1988;7:2043-52
24. Weiner DB, Liu J, Cohen JA, et al. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature 1989;339:230-31
25. Nikitin AY, Ballering LAP, Lyons J, et al. Early mutation of the neu (erbB-2) gene during ethylnitrosourea-induced oncogenesis in the rat Schwann cell lineage. Proc Natl Acad Sci USA 1991;88:9939-43
26. Sherman L, Sleeman JP, Hennigan RF, et al. Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro. Oncogene 1999;18:6692-99
27. Schlegel J, Trenkle T, Stumm G, et al. Growth inhibition by dominant-negative mutations of the new-encoded oncoprotein. Int J Cancer 1997;70: 78-83
28. Kindler-Rohrborn A, Kolsch BU, Fischer C, et al. Ethylnitrosourea-induced development of malignant schwannomas in the rat: two distinct loci on chromosome 10 involved in tumor susceptibility and oncogenesis. Cancer Res 1999;59:1109-14
29. Falls DL. Neuregulins: Functions, forms, and signaling strategies. Exp Cell Res 2003;284:14-30
30. Dong Z, Brennan A, Liu N, et al. Neu differentiation factor is a neuron-glia signal and regulates survival, proliferation and maturation of rat Schwann cell precursors. Neuron 1995;15:585-96
31. Rahmatullah M, Schroering A, Rothblum K, et al. Synergistic regulation of Schwann cell proliferation by heregulin and forskolin. Mol Cell Biol 1998;18:6245-52
32. Morrissey TK, Levi ADO, Nuijens A, et al. Axon-induced mitogenesis of human Schwann cells involves heregulin and p185erbB2. Proc Natl Acad Sci USA 1995;92:1431-35
33. Grinspan JB, Marchionni MA, Reeves M, et al. Axonal interactions regulate Schwann cell apoptosis in developing peripheral nerve: Neuregulin receptors and the role of neuregulins. J Neurosci 1996;16:6107-18
34. Syroid DE, Maycox PR, Burrola PG, et al. Cell death in the Schwann cell lineage and its regulation by neuregulin. Proc Natl Acad Sci USA 1996; 93:9229-34
35. Huijbregts RPH, Roth KA, Schmidt RE, et al. Hypertrophic neuropathies and malignant peripheral nerve sheath tumors in transgenic mice overexpressing glial growth factor β3 in myelinating Schwann cells. J Neurosci 2003;23:7269-80
36. Brockes JP, Breakefield XO, Martuza RL. Glial growth factor-like activity in Schwann cell tumors. Ann Neurol 1986;20:317-22
37. DeClue JE, Heffelfinger S, Benvenuto G, et al. Epidermal growth factor receptor expression in neurofibromatosis type 1-related tumors and NF1 animal models. J Clin Invest 2000;105:1233-41
38. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor receptor signaling pathways are associated with tumorigenesis in the Nf1:p53 mouse tumor model. Cancer Res 2002;62:4507-13
39. Yarden Y, Sliwkowski M. Untangling the erbB signaling network. Natl Rev Mol Cell Biol 2001;2:127-37
40. Perry A, Kunz SN, Fuller CE, et al. Differential NF1, p16, and EGFR patterns by interphase cytogenetics (FISH) in malignant peripheral nerve sheath tumor (MPNST) and morphologically similar spindle cell neoplasms. J Neuropathol Exp Neurol 2002;61:702-9
41. Zhang Y-W Vande Woude GF. HGF/SF-Met signaling in the control of branching morphogenesis and invasion. J Cell Biochem 2003;88: 408-17
42. Ma PC, Maulik G, Christensen J, et al. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Met Rev 2003;22:309-25
43. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Natl Rev Mol Cell Biol 2003;4:33-45
44. Krasnoselsky A, Massay MJ, DeFrances MC, et al. Hepatocyte growth factor is a mitogen for Schwann cells and is present in neurofibromas. J Neurosci 1994;14:7284-90
45. Rao UN, Sonmez-Alpan E, Michalopoulos GK. Hepatocyte growth factor and c-MET in benign and malignant peripheral nerve sheath tumors. Hum Pathol 1997;28:1066-70
46. Fukuda T, Ichimura E, Shinozaki T, et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol Int 1998;48:757-62
47. Watanabe T, Oda Y, Tamiya S, et al. Malignant peripheral nerve sheath tumor arising within neurofibroma: An immunohistochemical analysis in the comparison between benign and malignant components. J Clin Pathol 2001;54:631-36
48. Su W, Gutmann DH, Perry A, et al. CD44-independent hepatocyte growth factor/c-Met autocrine loop promotes malignant peripheral nerve sheath tumor cell invasion in vitro. Glia 2004;45:297-306
49. Oliveira SH, Lukacs NW. Stem cell factor: a hemopoietic cytokine with important targets in asthma. Curr Drug Targets Inflamm Allergy 2003;2: 313-18
50. Hirota S, Nomura S, Asada H, et al. Possible involvement of c-kit receptor and its ligand in increase of mast cells in neurofibroma tissues. Arch Pathol Lab Med 1993;117:996-99
51. Ryan JJ, Klein KA, Neuberger TJ, et al. Role for the stem cell factor/KIT complex in Schwann cell neoplasia and mast cell proliferation associated with neurofibromatosis. J Neurosci Res 1994;37:415-32
52. Demitsu T, Murata S, Kakurai M, et al. Malignant schwannoma-derived cells support human skin mast cell survival in vitro. J Dermatol Sci 1998;16:129-34
53. Yang F-C, Ingram DA, Chen S, et al. Neurofibromin-deficient Schwann cells secrete a potent migratory stimulus for Nf1+/- mast cells. J Clin Invest 2003;112:1851-61
54. Ingram DA, Yang FC, Travers JB, et al. Genetic and biochemical evidence that haploinsufficiency of the Nf1 tumor suppressor gene modulates melanocyte and mast cell fates in vivo. J Exp Med 2000;191: 181-88
55. ras and the hematopoietic-specific Rho GTPase, Rac2, cooperate to alter the proliferation of neurofibromin-deficient mast cells in vivo and in vitro. J Exp Med 2001;194:57-69
56. Badache A, Muja N, DeVries GH. Expression of Kit in neurofibromin- deficient human Schwann cells: Role in Schwann cell hyperplasia associated with type 1 neurofibromatosis. Oncogene 1998;17:795-800
57. Davis JB Stroobant P. Platelet-derived growth factors and fibroblast growth factors are mitogens for rat Schwann cells. J Cell Biol 1990;110: 1353-60
58. Hardy M, Reddy UR, Pleasure D. Platelet-derived growth factor and regulation of Schwann cell proliferation in vivo. J Neurosci Res 1992;31: 254-62
59. Kadono T, Kikuchi K, Nakagawa H, et al. Expressions of various growth factors and their receptors in tissues from neurofibroma. Dermatology 2000;201:10-14
60. Kadono T, Soma Y, Takehara K, et al. The growth regulation of neurofibroma cells in neurofibromatosis type-1: Increased responses to PDGF-BB and TGF-beta 1. Biochem Biophys Res Commun 1994;198:827-34
61. Badache A, DeVries GH. Neurofibrosarcoma-derived Schwann cells overexpress platelet-derived growth factor (PDGF) receptors and are induced to proliferate by PDGF BB. J Cell Physiol 1998;177: 334-42
62. Dang I, DeVries GH. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor BB. J Neurosci Res, In press
63. Kadomatsu K, Muramatsu T. Midkine and pleiotrophin in neural development and cancer. Cancer Lett 2004;204:127-43
64. Mashour GA, Wang HL, Manzano-Cabal R, et al. Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol 1999;113:398-402
65. Mashour GA, Ratner N, Khan GA, et al. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene 2001;20:97-105
66. Mirsky R, Jessen KR. Schwann cell development, differentiation and myelination. Curr Opin Neurobiol 1996;6:89-96
67. Parkinson DB, Dong Z, Bunting H, et al. Transforming growth factor β (TGFβ) mediates Schwann cell death in vitro and in vivo: Examination of c-Jun activation, interactions with survival signals, and the relationship of TGFβ-mediated death to Schwann cell differentiation. J Neurosci 2001; 21:8572-85
68. Yamate J, Yasui H, Benn SJ, et al. Characterization of newly established tumor lines from a spontaneous malignant schwannoma in F344 rats: Nerve growth factor production, growth inhibition by transforming growth factor β1, and macrophage-like phenotype expression. Acta Neuropathol 2003;106:221-33
69. McLaughlin ME, Jacks T. Progesterone receptor expression in neurofibromas. Cancer Res 2003;63:752-55
70. Martuza RL, MacLaughlin DT, Ojemann RG. Specific estradiol binding in schwannomas, meningiomas, and neurofibromas. Neurosurgery 1981; 9:665-71
71. Carpenter G. ErbB-4: mechanism of action and biology. Exp Cell Res 2003;284:66-77